FormWeb • cycloSPORINE

Oregon Department of Corrections

Approved Formulary

QR Code

Add Formweb to your mobile device

Android iOS

February P&T meeting minutes have been posted.

Oregon Department of Corrections

Approved Formulary

Search results for:

cycloSPORINE

cycloSPORINE

Hazardous Drugs Handling Guide (Group 2: Non-Antineoplastic)
Cell Status NFISA

Brand names: CycloSPORINE Modified, Gengraf, Neoral, SandIMMUNE, SANDIMUNE

Form	Strength
CAPSULE, ORAL	100 mg; modified 25 mg; modified 100 mg
LIQUID, ORAL	modified 100 mg/mL
SOLUTION, INJECTABLE	50 mg/mL

Additional Information:

Please note that modified cyclosporine (Neoral) is not bioequivalent to cyclosporine (Sandimmune) and cannot be used interchangeably.

FEBRUARY 2023 P&T MINUTES

OCTOBER 2021 P&T MINUTES

JUNE 2017 P&T MINUTES

Last updated: Mar. 14, 2023

Black Box Warning: Infection, neoplasm, nephrotoxicity risk
FDA Drug Safety: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research for Neoral (Cyclosporine) Soft Gelatin Capsule and Neoral (Cyclosporine) Oral Solution

This site is intended for the staff of Oregon Department of Corrections.
While others may view accessible pages, Oregon Department of Corrections makes no warranty, express or implied,
as to the use of this information outside of Oregon Department of Corrections.

Copyright © 2024 Rpharmy, LLC All Rights Reserved